Last reviewed · How we verify
Retin-A® 0.1% Cream
At a glance
| Generic name | Retin-A® 0.1% Cream |
|---|---|
| Sponsor | Sol-Gel Technologies, Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Development of Products Based on Secretom From Stem Cell Conditioned Medium for Melasma Therapy (NA)
- Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma (PHASE4)
- MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3 (PHASE1)
- To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Retin-A® 0.1% Cream CI brief — competitive landscape report
- Retin-A® 0.1% Cream updates RSS · CI watch RSS
- Sol-Gel Technologies, Ltd. portfolio CI